0.040
0.000
(0.00%)
Delayed:
3:18PM EDT
TSE
data delayed by 15 mins -
Disclaimer
Currency in CAD
| Range | 0.04 - 0.04 |
| 52 week | 0.03 - 0.13 |
| Open | 0.04 |
| Vol / Avg. | 107,500.00/106,353.00 |
| Mkt cap | 7.71M |
| P/E | - |
| Div/yield | - |
| EPS | -0.06 |
| Shares | 192.87M |
| Beta | 1.02 |
| Inst. own | - |
Events
May 27, 2013
Q1 2013 Isotechnika Inc. Earnings Release
|
|
Key stats and ratios
| Q3 (Sep '12) | 2011 | |
| Net profit margin | -1979.07% | -259.56% |
| Operating margin | -1979.07% | -694.19% |
| EBITD margin | - | -590.60% |
| Return on average assets | -81.39% | -19.74% |
| Return on average equity | -227.18% | -38.12% |
| Employees | 26 | - |
| Carbon Disclosure Rating | - | - |
Address
5120-75 Street
EDMONTON, AB T6E 6W2
Canada
+1-780-4871600 (Phone)
+1-780-4844105 (Fax)
EDMONTON, AB T6E 6W2
Canada
+1-780-4871600 (Phone)
+1-780-4844105 (Fax)
Website links
External links
Discussion Group - Google Finance
Advertisement
Description
Operates as a biopharmaceutical company. The Company is primarily focused on the development of immunosuppressive drugs for use in the treatment of autoimmune diseases and the prevention of organ rejection in transplantation.
Officers and directors
| Peter Wijngaard Ph.D. | Independent Chairman of the Board | |
| Robert T. Foster Ph.D. | President, Chief Executive Officer, Director | |
| Dennis Bourgeault | Chief Financial Officer, Corporate Secretary | |
| Launa Aspeslet Ph.D. | Chief Operating Officer | |
| Derrick Freitag Ph.D. | Chief Scientific Officer | |
| Robert Huizinga | Vice President - Clinical Affairs | |
| Prakash Gowd | Independent Director | |
| Donald W. Wyatt | Independent Director |